American Express, Eli Lilly, Humana And More: CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Sarat Sethi picked American Express Company AXP as he expects much more spending from millennials.

American Express CEO Stephen Squeri recently said he is not seeing a slowdown in demand for premium and fee-paying cards.

Bryn Talkington of Requisite Capital Management named ProShares K-1 Free Crude Oil Strategy ETF OILK as her final trade.

See Also: $1000 Invested In American Express 15 Years Ago Would Be Worth This Much Today

Stephen Weiss of Short Hills Capital Partners picked Humana Inc. HUM.

Cigna Group CI reportedly ended its attempt to negotiate an acquisition deal with rival Humana after the pair disagreed on price terms.

Don’t forget to check out our premarket coverage here

Joseph Terranova of Virtus Investment Partners said Eli Lilly and Company LLY continues to push higher.

Eli Lilly recently announced the detailed results from the SURMOUNT-4 Phase 3 study evaluating the safety and efficacy of Zepbound (tirzepatide) compared to a placebo for obesity with weight-related comorbidities, excluding type 2 diabetes.

Price Action:

• Humana shares gained 1.3% to close at $488.09 on Wednesday.
• American Express gained 2.1% to $174.56.
• Eli Lilly gained 2.2% to $597.50.
• ProShares K-1 Free Crude Oil Strategy ETF added 1.8% during Wednesday’s session.

Check This Out: Top 5 Tech And Telecom Stocks That May Crash In December

Image: Pixabay, edited with Canva